Algeta's financial calendar 2010
(Thomson Reuters ONE) - Oslo, Norway, 25 January 2010 - Algeta ASA (OSE:ALGETA), the cancer therapeuticscompany, announces it's financial calendar for 201019. Feb. Presentation of the annual accounts (08:00 CET)22. April General meeting07. May Presentation of first quarter report (09:45 CET)13. Aug. Presentation of second quarter report (09:45 CET)12. Nov. Presentation of third quarter report (09:45 CET)The presentations will be held at Hotel Continental, Oslo. Algeta reserves theright to revise the dates. The calendar is available in the report for the thirdquarter 2009 and on www.algeta.com. ###For further information, please contact Andrew Kay, CEO +47 2300 7990 / +47 4840 1360 (mob) ?stein Soug, CFO +47 2300 7990 / +47 9065 6525 (mob) post(at)algeta.com International media enquiries: +44 207 638 9571 Mark Swallow/Helena Galilee/David mark.swallow(at)citigatedr.co.uk Dible Citigate Dewe Rogerson US investor enquiries: +1 646 378 2928 Jessica Lloyd jlloyd(at)troutgroup.com The Trout Group About AlgetaAlgeta ASA is a cancer therapeutics company built on world-leading, proprietarytechnology. Algeta is developing a new generation of targeted cancertherapeutics (alpha-pharmaceuticals) that harness the unique characteristics ofalpha particle emitters and are potent, well-tolerated and convenient to use.Algeta's lead alpha-pharmaceutical candidate, Alpharadin (based on radium-223),has blockbuster potential for treating bone metastases arising from multiplemajor cancer types, owing to its bone-targeting nature, potent efficacy(therapeutic and palliative) and benign, placebo-like safety profile.Development of Alpharadin is most advanced targeting bone metastases resultingfrom hormone-refractory prostate cancer (HRPC), and it entered an internationalphase III clinical trial (ALSYMPCA) in mid-2008 based on compelling clinicalresults from a comprehensive phase II program. This trial is currently open forrecruitment.In September 2009, Algeta entered into an global agreement with Bayer HealthcareAG for the development and commercialization of Alpharadin. As part of theagreement, Algeta retains an option to co-promote Alpharadin in the UnitedStates and to share profits from future sales.Algeta is also developing other technologies for deliveringalpha-pharmaceuticals. These include methods to enhance the potency oftherapeutic antibodies and other tumor-targeting molecules by linking them tothe alpha particle emitter thorium-227. The Company is headquartered in Oslo,Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange inMarch 2007 (Ticker: ALGETA).Alpharadin and Algeta are trademarks of Algeta ASA.Forward-looking StatementThis news release contains forward-looking statements and forecasts based onuncertainty, since they relate to events and depend on circumstances that willoccur in the future and which, by their nature, will have an impact on resultsof operations and the financial condition of Algeta. There are a number offactors that could cause actual results and developments to differ materiallyfrom those expressed or implied by these forward-looking statements. Thesesfactors include, among other things, risks associated with technologicaldevelopment, the risk that research & development will not yield new productsthat achieve commercial success, the impact of competition, the ability to closeviable and profitable business deals, the risk of non-approval of patents notyet granted and difficulties of obtaining relevant governmental approvals fornew products. ###This information is subject of the disclosure requirements acc. to §5-12 vphl(Norwegian Securities Trading Act)[HUG#1376950] Financial calendar 2010: http://hugin.info/134655/R/1376950/338082.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:Leseranfragen:PresseKontakt / Agentur:Bereitgestellt von Benutzer: hugin
Datum: 25.01.2010 - 12:25 Uhr
Sprache: Deutsch
News-ID 1009418
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Anmerkungen:
Diese Pressemitteilung wurde bisher
114 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"
Algeta's financial calendar 2010
"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA
(
Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum
Haftungsauschluß (gemäß
TMG - TeleMedianGesetz) und dem
Datenschutz (gemäß der
DSGVO).
